The clinical significance of lymphocytes activation hi patients with multiple sclerosis
Ling Zhang
Abstract
Ling Zhang
Abstract
Objective:To analyze the lymphocyte activation from patients with different activities of multiple sclerosis (MS) and its clinical signifiance. Methods: The positive percentage of CD69 and HLA-DR were determined on peripheral blood (PB) or cerebrospinal fluid (CSF) lymphocytes by flow cytometry from 28 patients with relapsing-remitting MS (relapses n - 20, remission n = 8) , 12 patients with relapse MS and 11 patients with relapse MS after glucocorticoid treatment. ResultS:The percentage of HLA-DR+ and CD3+ /HLA-DR+ on PB lymphocytes in relapses MS group were higher than in remission MS group and controls. The percentage of CD3+ /HLA-DR+ on PB lymphocytes in remission MS group were higher than in controls. The percentage of CD69+ , HLA-DR+ and CD3+ /HLA-DR+ were higher in CSF than in PB of patients with relapse MS. There was no significant correlation between the levels of CD69+ , HLA-DR+ , CDS+ /HLA-DR+ and the time of onset of clinical relapse, duration, clinical disability scale score(EDSS) . In patients with relapse MS, there was significant positive correlation between CD69+ expression on CSF lymphocytes and blood brain barrier damage, intravenous glucocorticoid treatment caused a significant changes in the positive percentage of HLA-DR on PB lymphocytes. Conclusion:The findings support that lymphocyte activation involvement of MS pathogenesis. Lymphocyte activation may be as a marker of disease activity in MS.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective:To analyze the lymphocyte activation from patients with different activities of multiple sclerosis (MS) and its clinical signifiance. Methods: The positive percentage of CD69 and HLA-DR were determined on peripheral blood (PB) or cerebrospinal fluid (CSF) lymphocytes by flow cytometry from 28 patients with relapsing-remitting MS (relapses n - 20, remission n = 8) , 12 patients with relapse MS and 11 patients with relapse MS after glucocorticoid treatment. ResultS:The percentage of HLA-DR+ and CD3+ /HLA-DR+ on PB lymphocytes in relapses MS group were higher than in remission MS group and controls. The percentage of CD3+ /HLA-DR+ on PB lymphocytes in remission MS group were higher than in controls. The percentage of CD69+ , HLA-DR+ and CD3+ /HLA-DR+ were higher in CSF than in PB of patients with relapse MS. There was no significant correlation between the levels of CD69+ , HLA-DR+ , CDS+ /HLA-DR+ and the time of onset of clinical relapse, duration, clinical disability scale score(EDSS) . In patients with relapse MS, there was significant positive correlation between CD69+ expression on CSF lymphocytes and blood brain barrier damage, intravenous glucocorticoid treatment caused a significant changes in the positive percentage of HLA-DR on PB lymphocytes. Conclusion:The findings support that lymphocyte activation involvement of MS pathogenesis. Lymphocyte activation may be as a marker of disease activity in MS.
Key concepts: Multiple sclerosis, Medicine, Cerebrospinal fluid, Internal medicine, CD3, Glucocorticoid, Lymphocyte, CD69